Polymorphs of bromfenac sodium and methods for preparing bromfenac sodium polymorphs
Different polymorphs of bromfenac sodium may be prepared and interconverted using crystallization/recrystallization, drying and/or hydration techniques.
1. A composition consisting of bromfenac sodium Form I characterized by a powder x-ray diffraction pattern in accordance with that shown in FIG. 1 .
2. A method for making a pharmaceutical formulation comprising mixing the composition of claim 1 and at least one excipient to provide the pharmaceutical formulation.
3. The method of claim 2 , wherein the at least one excipient is selected from the group consisting of at least one of carriers, solvents, preservatives, stabilizers, surfactants, pH adjusting agents, diluents, and fillers.
4. The method of claim 2 , wherein the at least one excipient comprises a water soluble polymer.
5. The method of claim 2 , wherein the at least one excipient comprises a preservative, a chelating agent, a pH-adjusting agent, a water soluble polymer, a sulfite, water, and a buffer system.
6. The method of claim 5 , wherein the pH-adjusting agent comprises sodium hydroxide, the water soluble polymer comprises polyvinyl pyrrolidone, the sulfite comprises sodium sulfite, and the buffer system comprises boric acid and sodium borate.
7. The method of claim 6 , wherein the chelating agent comprises sodium edetate.
8. A method for reducing inflammation comprising administering the pharmaceutical formulation made by the method of claim 2 to an eye of a human patient in need of such treatment, wherein the pharmaceutical formulation is an ophthalmic composition.
9. The method of claim 8 , wherein the inflammation is a result of an operative procedure or surgery.
10. The method of claim 8 , wherein the pharmaceutical formulation contains less than 100 ppm aluminum, boron, and manganese in total and less than 30 ppm of each of these elements.
11. The method of claim 8 , wherein the pharmaceutical formulation does not contain more than 0.15% AUC of any process impurity of bromfenac sodium degradation product.
12. A method for reducing pain comprising administering the pharmaceutical formulation made by the method of claim 2 to an eye of a human patient in need of such treatment, wherein the pharmaceutical formulation is an ophthalmic composition.
13. The method of claim 12 , wherein the pharmaceutical formulation contains less than 100 ppm aluminum, boron, and manganese in total and less than 30 ppm of each of these elements.
14. The method of claim 12 , wherein the pharmaceutical formulation does not contain more than 0.15% AUC of any process impurity of bromfenac sodium degradation product.
15. A vial containing the pharmaceutical formulation made by the method of claim 2 .
16. The vial of claim 15 , wherein the pharmaceutical formulation is an ophthalmic composition.
17. The vial of claim 15 , wherein the pharmaceutical formulation is an ophthalmic composition in the form of eye drops or an eye ointment.
18. The vial of claim 15 , wherein the formulation is in the form of a solid, an ointment, or a suspension.
19. The vial of claim 15 , wherein the formulation is in the form of a solid, an ointment, or a suspension.
20. A composition consisting of bromfenac sodium Form I characterized by a powder x-ray diffraction pattern having main peaks expressed as 2-theta at about 4.4, 8.8, 9.4, 12.1, 15.2, 15.9, 17.6, 18.2, 18.8, 20.2, 21.2, 24.7, 28.4, and 32.4 degrees.
21. A method for making a pharmaceutical formulation comprising mixing the composition of claim 20 and at least one excipient to provide the pharmaceutical formulation.
22. A vial containing the pharmaceutical formulation made by the method of claim 21 .
23. The vial of claim 22 , wherein the pharmaceutical formulation is an ophthalmic composition.
24. The vial of claim 22 , wherein the pharmaceutical formulation is an ophthalmic composition in the form of eye drops or an eye ointment.
25. A method for reducing inflammation comprising administering the pharmaceutical formulation made by the method of claim 21 to an eye of a human patient in need of such treatment, wherein the pharmaceutical formulation is an ophthalmic composition.
26. The method of claim 25 , wherein the inflammation is a result of an operative procedure or surgery.
27. The method of claim 25 , wherein the pharmaceutical formulation contains less than 100 ppm aluminum, boron, and manganese in total and less than 30 ppm of each of these elements.
28. The method of claim 25 , wherein the pharmaceutical formulation does not contain more than 0.15% AUC of any process impurity of bromfenac sodium degradation product.
29. The method of claim 21 , wherein the at least one excipient is selected from the group consisting of at least one of carriers, solvents, preservatives, stabilizers, surfactants, pH adjusting agents, diluents, and fillers.
30. The method of claim 21 , wherein the at least one excipient comprises a water soluble polymer.
31. The method of claim 21 , wherein the at least one excipient comprises a preservative, a chelating agent, a pH-adjusting agent, a water soluble polymer, a sulfite, water, and a buffer system.
32. The method of claim 31 , wherein the pH-adjusting agent comprises sodium hydroxide, the water soluble polymer comprises polyvinyl pyrrolidone, the sulfite comprises sodium sulfite, and the buffer system comprises boric acid and sodium borate.
33. The method of claim 32 , wherein the chelating agent comprises sodium edetate.
34. A method for reducing pain comprising administering the pharmaceutical formulation made by the method of claim 21 to an eye of a human patient in need of such treatment, wherein the pharmaceutical formulation is an ophthalmic composition.
35. The method of claim 34 , wherein the pharmaceutical formulation contains less than 100 ppm aluminum, boron, and manganese in total and less than 30 ppm of each of these elements.
36. The method of claim 34 , wherein the pharmaceutical formulation does not contain more than 0.15% AUC of any process impurity of bromfenac sodium degradation product.